A randomised evaluation of <scp>low‐dose</scp> cytosine arabinoside plus lenalidomide versus <scp>single‐agent low‐dose</scp> cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the <scp>LI</scp>‐1 trial
British journal of haematology